Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioma 4Urinary Bladder Neoplasms 3Wilms Tumor 2Rhabdoid Tumor 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Carcinoma, Transitional Cell 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 4Gemcitabine 3Biopsy 3eribulin 2cabozantinib 2atezolizumab 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1carotuximab 1avelumab 1Watchful Waiting 1Platinum 1Observation 1Nivolumab 1Lenalidomide 1Ipilimumab 1Interleukin-7 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Contrast Media 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Bortezomib 1Bevacizumab 1Arsenic Trioxide 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ureteral Neoplasms × erdafitinib × Clear all
NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡